The Blackmores Limited (ASX:BKL) share price will be one to watch on Tuesday after the release of its AGM update…
The post Blackmores (ASX:BKL) share price on watch after AGM update appeared first on Motley Fool Australia. –
The Blackmores Limited (ASX: BKL) share price will be one to watch this morning following the release of its annual general meeting update.
What was in Blackmores’ update?
As well as providing investors with a summary on how the health supplements company performed in FY 2020, management revealed its expectations for the current financial year.
According to the release, while no specific full year profit guidance has been given, it is anticipating full year profit growth in FY 2021. This is despite additional cost variances arising from Braeside manufacturing ownership in the first half of the year.
Though, management has warned that its profit growth will come predominantly from the second half of the financial year.
Looking beyond FY 2021, management notes that it has confidence in its renewed strategy and expects it to put the company back on a path to sustainable, profitable growth and in a position to restore future dividends.
No real update was given for its performance in the first quarter of the year. Though, management did advise that it has completed its restructuring, which is set to deliver $15 million of gross annualised savings from the second half.
It has also initiated a Leading Value Position (LVP) savings program, which will contribute to cost of goods sold savings of $10 million in FY 2021.
Global Therapeutics divestment.
In a separate announcement, Blackmores has revealed an agreement to sell its Global Therapeutics business to McPherson’s Ltd (ASX: MCP) for $27 million.
Chief Executive Officer, Alastair Symington, commented: “Fusion Health and Oriental Botanicals are wonderful brands which play an important role in the health and wellness routine of many Australians. While we have decided that Global Therapeutics is no longer part of of our strategic priorities, I want to acknowledge the unique value of these brands and believe Global Therapeutics will now have an opportunity to reach its true potential with McPherson’s.”
The transaction is scheduled for completion on 30 November. It remains subject to conditions in relation to the transfer of a minimum number of employees and material contracts and there being no material adverse change to the business.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- 5 things to watch on the ASX 200 next week
- McPherson’s (ASX:MCP) share price on watch on Wednesday after Q1 update
- Why I like ASX consumer staples shares in the current climate
- These were the worst performing shares on the ASX 200 last week
- Why a2 Milk, Blackmores, Ramelius, & Synlait Milk shares are tumbling lower
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Blackmores Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.